[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
D000069446:Atazanavir Sulfate; D001786:Blood Glucose / Q000378:metabolism*; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008055:Lipids / Q000097:blood*; D061466:Lopinavir; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000009:adverse effects / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use; D019562:Viral Load
D001786:Blood Glucose; D017320:HIV Protease Inhibitors; D008055:Lipids; D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D061466:Lopinavir; D000069446:Atazanavir Sulfate; D019438:Ritonavir
Atazanavir schont Fettstoffwechsel. Neuer PI mit günstigem metabolischen Profil.